LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective
- PMID: 32694249
- DOI: 10.1159/000509162
LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective
Abstract
The availability of recombinant follicle-stimulating hormone (FSH) and luteinizing hormone (LH) opens an opportunity to individualize ovarian stimulation. While the need for FSH in ovarian stimulation is universal, a question remains whether exogenous LH is beneficial. Previous population-based research showed that added LH is indicated in elderly and in profoundly LH depressed patients. This commentary explores potential individual patient parameters that may hint that this specific individual may prospectively need supplemented LH, irrespective of her age or experience from previous cycles. Specifically, it is suggested that in an antagonist protocol, the degree of LH recovery 24 h post first GnRH antagonist injection can identify those patients who may benefit from added LH. In addition, rising LH during the first 5 days of stimulation may predispose patients to a sharp LH drop following the first GnRH antagonist dose, and the need for added LH.
Keywords: GnRH antagonist; Individualized approach; Luteinizing hormone recovery; Ovarian stimulation; Supplemented luteinizing hormone.
© 2020 S. Karger AG, Basel.
Similar articles
-
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3. Hum Reprod. 2015. PMID: 25740882 Clinical Trial.
-
Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.Hum Reprod. 2013 Oct;28(10):2804-12. doi: 10.1093/humrep/det266. Epub 2013 Jul 9. Hum Reprod. 2013. PMID: 23838159 Clinical Trial.
-
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.Hum Reprod. 2005 May;20(5):1200-6. doi: 10.1093/humrep/deh741. Epub 2005 Jan 21. Hum Reprod. 2005. PMID: 15665010 Clinical Trial.
-
To add or not to add LH: consideration of LH concentration changes in individual patients.Reprod Biomed Online. 2005 Dec;11(6):664-6. doi: 10.1016/s1472-6483(10)61680-x. Reprod Biomed Online. 2005. PMID: 16417723 Review.
-
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3. Cochrane Database Syst Rev. 2017. PMID: 28537052 Free PMC article. Review.
Cited by
-
Researching the Phenomenon of Poor Ovarian Responders and Management Strategies in IVF: A Narrative Review.Acta Med Acad. 2022 Aug;51(2):108-122. doi: 10.5644/ama2006-124.379. Acta Med Acad. 2022. PMID: 36318003 Free PMC article. Review.
-
Luteal Phase Support Using Subcutaneous Progesterone: A Systematic Review.Front Reprod Health. 2021 Aug 6;3:634813. doi: 10.3389/frph.2021.634813. eCollection 2021. Front Reprod Health. 2021. PMID: 36303972 Free PMC article.
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
-
Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.Front Endocrinol (Lausanne). 2021 May 10;12:675670. doi: 10.3389/fendo.2021.675670. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34040586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
